Open Label Study to Evaluate the Efficacy of Etanercept Treatment in Subjects With Moderate to Severe Plaque Psoriasis Who Have Failed Therapy With Apremilast

Trial Profile

Open Label Study to Evaluate the Efficacy of Etanercept Treatment in Subjects With Moderate to Severe Plaque Psoriasis Who Have Failed Therapy With Apremilast

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 11 Jul 2017

At a glance

  • Drugs Etanercept (Primary)
  • Indications Plaque psoriasis
  • Focus Therapeutic Use
  • Sponsors Amgen
  • Most Recent Events

    • 05 Jul 2017 Planned End Date changed from 27 Nov 2017 to 19 Nov 2017.
    • 05 Jul 2017 Planned primary completion date changed from 23 Aug 2017 to 15 Aug 2017.
    • 05 Jul 2017 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top